Gamma delta T-cell immunotherapy - Beijing Doing Biomedical

Drug Profile

Gamma delta T-cell immunotherapy - Beijing Doing Biomedical

Alternative Names: γδ T-cell immunotherapy

Latest Information Update: 30 Nov 2015

Price : $50

At a glance

  • Originator Beijing Doing Biomedical
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastric cancer

Most Recent Events

  • 30 Nov 2015 Preclinical trials in Gastric cancer in China (unspecified route)
  • 30 Nov 2015 Beijing Doing Biomedical plans a phase I/II trial for Gastric cancer in China (NCT02585908)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top